Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Journal of Clinical Pharmacology|June 1, 1989
Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulationJ C Fleishaker, J P Phillips, M G Eller, et al.Biopharmaceutics & Drug Disposition|December 1, 1996
An investigation of the dose proportionality of deflazacort pharmacokineticsN Rao, V O Bhargava, D L Reynolds, et al.Journal of Pharmaceutical Sciences|February 1, 1985
Topical carbonic anhydrase inhibitors. III: Optimization model for corneal penetration of ethoxzolamide analoguesM G Eller, R D Schoenwald, J A Dixson, et al.Journal of Pharmaceutical Sciences|May 1, 1985
Topical carbonic anhydrase inhibitors IV: Relationship between excised corneal permeability and pharmacokinetic factorsM G Eller, R D Schoenwald, J A Dixson, et al.The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 20, 1999
Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part IA Keung, K Reith, M G Eller, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 11, 1998
Disposition and metabolism of 14C-rifapentine in healthy volunteersK Reith, A Keung, P C Toren, et al.Archives of Ophthalmology (Chicago, Ill. : 1960)|December 1, 1984
Ethoxzolamide analogue gel. A topical carbonic anhydrase inhibitorR A Lewis, R D Schoenwald, M G Eller, et al.Biopharmaceutics & Drug Disposition|April 1, 1992
Absence of food effects on the pharmacokinetics of terfenadineM G Eller, B J Walker, L Yuh, et al.Antimicrobial Agents and Chemotherapy|May 1, 1999
Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I studyA C Keung, R C Owens, M G Eller, et al.Journal of Clinical Pharmacology|March 1, 1992
Pharmacokinetics of terfenadine in healthy elderly subjectsM G Eller, B J Walker, P A Westmark, et al.Pageof 3